Appendix 4C - Quarterly - 31 March 2026
Filed with ASX · · 10 pages · English
Story so far
Earlier from Patrys
- $3.2 million Placement to Advance Clinical Trials
- Investor Presentation - Broker Meets Biotech
- RLS-2201 Manufacturing and Regulatory Pathway Initiated
- Appendix 4D - Half Year Accounts - 31 December 2025
- Appointment of Chief Executive Officer
Later from Patrys
- Patrys advances RLS-2202 toward Phase 1 Clinical Trial
- Patrys Secures 50% Revenue Share in IP Commercialisation
- Appendix 4C - Quarterly - 30 June 2026
- Investor Presentation - TechKnow Invest Roadshow
- Ethics Approval Secured for Phase 1A Clinical Trial
Follow Patrys into a list and get an email when it puts out news.
Follow Patrys